Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements (Tables)

v3.20.2
Research and Development Agreements (Tables)
6 Months Ended
Jun. 30, 2020
Schedule of Research and Development Revenues Disaggregated by Location

Research and development revenue is attributable to regions based on the location of the Company’s collaboration partner's parent company headquarters.  Research and development revenues disaggregated by location were as follows (in thousands):

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Japan

 

$

3,063

 

 

$

5,211

 

 

$

3,396

 

 

$

11,624

 

United States

 

 

2,977

 

 

 

 

 

 

4,444

 

 

 

 

Total research and development revenue

 

$

6,040

 

 

$

5,211

 

 

$

7,840

 

 

$

11,624

 

Millennium Pharmaceuticals Inc  
Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements

Research and development revenue from related party relates to revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda and were as follows (in thousands):

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Takeda Individual Project Agreement

 

 

 

 

 

 

 

 

 

 

 

54

 

Takeda Development and License Agreement

 

 

3,028

 

 

 

5,012

 

 

 

3,176

 

 

 

11,126

 

Takeda Multi-Target Agreement

 

 

35

 

 

 

199

 

 

 

220

 

 

 

444

 

Total research and development revenue

 

$

3,063

 

 

$

5,211

 

 

$

3,396

 

 

$

11,624

 

Takeda  
Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from Research and Development Agreements

At June 30, 2020 and December 31, 2019, the Company had deferred revenue, other liabilities for co-share payments and accounts receivable balances from the research and development agreements with Takeda, who is a related party, were as follows (in thousands):

 

 

 

June 30, 2020

 

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

 

Accounts receivable

 

$

3,167

 

 

$

408

 

Liabilities

 

 

 

 

 

 

 

 

Other current liabilities

 

$

5,325

 

 

 

 

Deferred revenue, current

 

 

5,218

 

 

 

8,780

 

Deferred revenue, non-current

 

 

1,849

 

 

 

441

 

Other liabilities

 

 

6,654

 

 

 

 

Total liabilities

 

$

19,046

 

 

$

9,221